Abbott's $670M Lesson: Read the Formula
Abbott's settlement this week, resolving roughly 2,000 infant formula cases brought by TorHoerman Law, Holland Law Firm, and Stranch, Jennings & Garvey, landed while the first federal formula trial against Mead Johnson was already underway.
$670 million. That's what it costs to learn, in the most expensive classroom in American litigation, that a product liability crisis doesn't negotiate itself down — it compounds. Abbott's settlement this week, resolving roughly 2,000 infant formula cases brought by TorHoerman Law, Holland Law Firm, and Stranch, Jennings & Garvey, landed while the first federal formula trial against Mead Johnson was already underway. The timing wasn't coincidence. It was arithmetic.
This is how mass tort litigation actually works, and it's a lesson that travels. The plaintiff's bar had been building the Necrotizing Enterocolitis cases for years before a single jury was seated. Thousands of families, premature infants, devastating outcomes allegedly linked to cow's milk-based formula — and two major manufacturers at the center of it. Abbott watched what was happening in state courts, watched the first federal trial begin against its co-defendant, and made the call. Not because it was the moral thing to do. Because the math changed the moment a jury box filled up.
Here's the negotiation principle inside that decision: your settlement leverage is highest in the window between the filing of the first trial date and the moment opening statements begin. Once the other side has committed fully to the courtroom — witness fees paid, exhibits printed, narrative locked — their incentive to resolve collapses. They've already spent the money. They've already built the story. But that morning before trial begins, when the bill for losing is suddenly concrete and the cost of the last move is visible? That window is where the real deal lives. Abbott used it. That's not weakness. That's precision.
The broader story is one that anyone running a business — or defending one — should absorb slowly. Mass tort exposure doesn't arrive as a single lawsuit. It arrives as a theory. First a handful of cases, dismissed or settled quietly. Then an MDL. Then a trial date. Then another. The moment a manufacturer loses one trial, every case behind it revalues upward. Abbott's lawyers understood that a $670 million settlement, painful as it is to sign, is a number they chose. A verdict after six weeks of testimony about premature infants is a number a jury chooses. Those are different exercises entirely.
There's a version of this story that applies in miniature every day in Malta — a contractor facing multiple breach claims, an employer with a pattern of termination disputes, a landlord whose identical lease clause is being challenged in three separate tribunal proceedings. The principle is the same. One adverse finding changes the value of every related dispute in your portfolio. Smart counsel identifies that inflection point before it arrives and resolves what can be resolved while the outcome is still a negotiation rather than a verdict.
I once took a case for a family — no money, no connections, no lawyer who would touch it. It was a clinical negligence matter involving a child. The institution on the other side had four in-house lawyers and a standard playbook: delay, exhaust, outlast. We didn't file immediately. We built the record for six months and then sent one letter that made the cost of continuing unmistakably clear. The case resolved before Christmas. That's the formula. Not litigation — leverage, applied at the moment when the other side can still feel what happens if they don't move.
The Mead Johnson trial continues. The jury that Abbott chose not to face is still seated. The verdict, when it arrives, will set the price for every defendant who thought they could outlast this one.
The move you make tomorrow: If your business has more than one unresolved dispute with the same factual pattern — same clause, same product, same conduct — instruct your legal counsel to map those cases together and identify the one with the weakest facts. Resolve that one first, on your terms, before a ruling in the worst case revalues every other dispute upward. Settlement sequencing is a strategy. Most clients never ask for it. Ask for it.
---
*Harvey Specter Jr. is Law, Business & Power Correspondent for News Beast by FreeMalta.com. He takes the cases nobody else will touch and writes about the ones everyone else missed.*